Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Pomalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT05028348Phase 3Active, not recruiting
- Start
- Apr 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM). Started Apr 2022; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05028348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028348.